Skip to main content

Table 1 Clinicopathological data

From: Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil

Clinicopathologic Diagnosis Histologic Diagnosis Gender Age (years) Follow-up (months) Relapses (n) First line treatment Stage
All patients
Median (std dev)
  11:10 M:F 53 (14) 63 (90) 3 (2)   
pcALCL* pcALCL M 48 43 1 Radiotherapy, CHOP, bortezomib T3bN0M0
pcALCL pcALCL M 33 22 1 Radiotherapy T3bN0M0
pcALCL pcALCL M 69 92 3 Radiotherapy T1bN1M0
pcALCL pcALCL F 73 26 N/A N/A T1aN1M1
pcALCL pcALCL M 32 117 3 ProMACE CytaBOM T3bN0M0
pcALCL pcALCL F 58 4 0 N/A T1aN0M0
pcALCL pcALCL M 46 7 0 Radiotherapy T1bN0M0
pcALCL pcALCL F 46 64 5 Excision T2aN0M0
pcALCL pcALCL M 83 17 0 None T2aN1M0
pcALCL - Median (std dev)   6:3 M:F 52 (17) 24 (37) 1 (2)   
Borderline pcALCL F 53 293 7 Excision T1aN0M0
Borderline Borderline F 58 110 3 None T3aN0M0
Borderline Borderline F 64 63 N/A Excision T3bN0M0
Borderline Borderline F 49 3 0 Prednisone T3bN0M0
Borderline - Median (std dev)   0:4 M:F 56 (6) 87 (108) 3 (3)   
LyP LyP-C F 34 214 5 Topical corticosteroid  
LyP* LyP-A F 47 334 4 Prednisone, cyclophosphamide  
LyP LyP-A M 57 86 N/A N/A  
LyP LyP-A F 29 118 4 Phototherapy^  
LyP LyP-A M 54 16 1 Methotrexate  
LyP LyP-A M 43 87 5 Phototherapy  
LyP LyP-A M 61 11 N/A Methotrexate  
LyP LyP-A M 59 40 1 Topical corticosteroid  
LyP - Median (std dev)   5:3 M:F 51 (11) 87 (103) 4 (2)   
  1. CHOP Cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone; LyP Lymphomatoid papulomatosis, LyP-A Lymphomatoid papulomatosis type A, LyP-C Lymphomatoid papulomatosis type C, N/A Not available., pcALCL primary cutaneous anaplastic large cell lymphoma, ProMACE CytaBOM Cyclophosphamide, hydroxydaunorubicin, etoposide, cytarabine, bleomycin, oncovin, methotrexate and prednisone, std. dev standard deviation
  2. *Subsequent diagnosis of mycosis fungoides; ^Phototherapy = psoralen combined UVA